Variable gene expression within human tyrosinemia type 1 liver may reflect region-specific dysplasia.
Patients with hereditary tyrosinemia type 1 have a deficiency of fumarylacetoacetate hydrolase (FAH) and develop progressive hepatocellular dysfunction with a high risk of malignant transformation. Serum alpha-fetoprotein levels are frequently elevated in these patients; therefore, this commonly used marker of tumorigenesis is inadequate. To date, no literature exists describing the hepatic gene alterations in patients with this disease. We analyzed the expression of a panel of proliferation associated and liver-specific genes in the liver of a 33 month-old girl at the time of orthotopic liver transplantation. This study provides information that may be useful in developing markers for malignancy and understanding the pathogenesis of this disease. Gene expression patterns of two regenerating nodules and total liver from the patient with FAH deficiency were compared with control donor liver. Liver-specific and growth-induced genes with altered expression in the tyrosinemic liver included several functional classes: structural proteins (actin, thrombospondin), transcription factors (c-fos, egr-1, C/EBPalpha), liver-specific enzymes (glucose-6-phosphatase [G6Phase], and secreted factors (insulin-like growth factor binding protein 1 [GFBP-1]. Isolated macronodules demonstrated varied patterns of expression, suggesting that they do not form a homogeneous cellular environment. In the tyrosinemic liver, IGFBP-1 messenger RNA expression was high and G6Phase messenger RNA was not detectable. Although G6Phase and IGFBP-1 are coexpressed in regenerating liver, immunohistochemistry in the tyrosinemic liver demonstrated a mutually exclusive distribution for the two proteins in a tissue section with features of dysplasia. We propose that cells in these areas may have an aberrant transcription factor and growth factor "milieu" that leads to altered gene and protein expression. These molecular alterations are reflected in dysplastic histologic changes and may ultimately predispose to the development of malignancy.
Haber
B A
BA
Division of Gastroenterology and Nutrition, Department of Pediatrics, Children's Hospital of Philadelphia, PA 19104-6145, USA.
Chuang
E
E
Lee
W
W
Taub
R
R
D000592:Amino Acid Metabolism, Inborn Errors / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D015415:Biomarkers; D014408:Biomarkers, Tumor; D002453:Cell Cycle; D002675:Child, Preschool; D005260:Female; D015870:Gene Expression; D018507:Gene Expression Regulation, Developmental; D006801:Humans; D006867:Hydrolases / Q000172:deficiency / Q000235:genetics; D008099:Liver / Q000378:metabolism* / Q000473:pathology*; D008113:Liver Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D016031:Liver Transplantation; D008279:Magnetic Resonance Imaging; D014176:Protein Biosynthesis; D011506:Proteins / Q000235:genetics; D012307:Risk Factors; D000509:alpha-Fetoproteins / Q000032:analysis
D015415:Biomarkers; D014408:Biomarkers, Tumor; D011506:Proteins; D000509:alpha-Fetoproteins; D006867:Hydrolases; C020156:fumarylacetoacetase